Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829552 · ClinicalTrials.gov registry record
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
A clinical trial of COVID-19, sponsored by Corewell Health East.
- Completed
- Registry status
- 704
- Enrollment target
- 1
- Study location
NCT04829552: Completed study of COVID-19, sponsored by Corewell Health East.
NCT04829552 is a study of COVID-19 that has completed, run by Corewell Health East. The registered enrollment target is 704 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04829552, a study of COVID-19, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- 704 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
Conditions Studied
Study Locations (1)
Michigan
- Beaumont Health System (BHS) - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2020-04-15 |
What the finished NCT04829552 record still lists
NCT04829552 is an observational study that tracks outcomes without assigning an intervention. The registered 704 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04829552 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04829552 about?
NCT04829552 is a clinical study titled "Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units". This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to ...
What is the current status of trial NCT04829552?
This trial is currently completed. The enrollment target is 704 participants. The study started on 2020-03-10. Estimated completion is 2020-04-15.
What conditions does trial NCT04829552 study?
This clinical trial studies the following conditions: COVID-19.
Who is sponsoring clinical trial NCT04829552?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829552 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04829552's enrollment target sits among peer trials
704 94th of 298 higher than 205 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI